Sofpironium bromide (formerly BBI-4000; BBI-4000; Ecclock) is a potent anticholinergic drug approved in Japan in 2020 as a 5% gel for the treatment of primary axillary hyperhidrosis (excessive underarm sweating). Sofpironium bromide is a new chemical entity belonging to the class of medications called anticholinergics. Anticholinergics block the action of acetylcholine, a chemical that transmits signals within the nervous system that are responsible for a range of bodily functions, including activation of the sweat glands. Sofpironium bromide was retrometabolically designed. It reduces sweating by inhibiting M3 muscarinic receptors in eccrine glands at the application site, and exhibits high affinity for the M1, M2, M4 and M5 muscarinic receptor subtypes.

纯度：≥98%

CAS：1628106-94-4